Trial Profile
ADEPT: Phase II neo-adjuvant study of Androgen Deprivation Therapy (Degarelix) and Erdafitinib in high-risk localized prostate cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Erdafitinib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADEPT
- 11 Feb 2021 Planned End Date changed from 30 Sep 2019 to 12 Mar 2021.
- 11 Feb 2021 Status changed from recruiting to discontinued.Reason: The first phase of recruitment is complete. The end points from phase one were not met in order to continue to the second phase of recruitment.
- 19 Jul 2019 Planned End Date changed from 1 Jan 2020 to 30 Sep 2019.